Compare
Corbus Pharmaceuticals Holdings, Inc. vs Climb Bio, Inc. vs Eledon Pharmaceuticals, Inc. vs Gyre Therapeutics, Inc.
| Latest fiscal year | Corbus Pharmaceuticals Holdings, Inc. CRBP | Climb Bio, Inc. CLYM | Eledon Pharmaceuticals, Inc. ELDN | Gyre Therapeutics, Inc. GYRE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $116.59M |
| Revenue growth (YoY) | n/a | n/a | n/a | +10.2% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/a | 9.9% |
| Net margin | n/a | n/a | n/a | 8.5% |
| Net income | -$78.54M | -$59.85M | -$45.62M | $9.88M |
| EPS (Diluted) | -$5.90 | -$0.88 | -$0.52 | $0.02 |
| Operating cash flow | -$64.49M | -$54.36M | -$62.34M | $1.01M |
| Free cash flow | -$64.50M | -$54.54M | n/a | -$180.0K |
| Cash & equivalents | $28.49M | $35.69M | $22.81M | $37.07M |
| Total assets | $168.19M | $167.74M | $169.01M | $166.13M |
| Total liabilities | $20.69M | $7.27M | $32.23M | $23.85M |
| Shareholders' equity | $147.50M | $160.47M | $81.08M | $106.03M |
| Return on year-end equity | -53.2% | -37.3% | -56.3% | 9.3% |
| Shares outstanding | 17.61M | 47.77M | 75.43M | 91.31M |
Revenue, most recent five fiscal years
| Fiscal year | Corbus Pharmaceuticals Holdings, Inc. | Climb Bio, Inc. | Eledon Pharmaceuticals, Inc. | Gyre Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2022-12-31 | n/a | $0 Ended 2016-12-31 | $116.59M Ended 2025-12-31 |
| 1 year earlier | $881.7K Ended 2021-12-31 | n/a | $0 Ended 2015-12-31 | $105.76M Ended 2024-12-31 |
| 2 years earlier | $3.94M Ended 2020-12-31 | n/a | n/a | $113.45M Ended 2023-12-31 |
| 3 years earlier | $36.14M Ended 2019-12-31 | n/a | n/a | $102.29M Ended 2022-12-31 |
| 4 years earlier | $4.82M Ended 2018-12-31 | n/a | n/a | $7.34M Ended 2021-12-31 |